Juno Therapeutics Inc Email & Phone number of top level executives

Juno Therapeutics Inc

Juno Therapeutics is a US biotechnology company focused on developing innovative immunotherapies to treat cancer. Founded in 2013 and located in Seattle, Washington, Juno Therapeutics utilizes CAR-T cell therapy to create customized immune cells that can target, attack and eliminate cancer cells. The company's leading product, JCAR017, is being developed for the treatment of lymphoma and has shown promising results in clinical trials. Juno Therapeutics was acquired by Celgene Corporation in 2018, which in turn was acquired by Bristol Myers Squibb in 2019.